Characteristics of patients and treatment_
| Characteristics | Numbers | % |
|---|---|---|
| Age | ||
| <40 years | 13 | 25.2 |
| >40 years | 44 | 74.8 |
| Menopausal Status | ||
| premenopausal | 32 | 56.4 |
| postmenopausal | 22 | 38.2 |
| perimenopausal | 3 | 5.4 |
| Breast | ||
| Right | 22 | 38.2 |
| Left | 33 | 57.4 |
| Bilateral | 2 | 3.4 |
| Tumour size | ||
| T1 | 20 | 34.6 |
| T2 | 30 | 51.9 |
| T3 | 6 | 11.7 |
| T4 | 1 | 1.8 |
| Lymph nodes | ||
| N0 | 22 | 8.2 |
| N1 | 18 | 30.8 |
| N2 | 6 | 11.7 |
| N3 | 11 | 19.3 |
| Stage | ||
| I | 10 | 17.3 |
| II | 30 | 51.9 |
| III | 17 | 30.8 |
| Hormone receptor status | ||
| Positive | 34 | 58.8 |
| Negative | 23 | 41.2 |
| Surgery | ||
| MRM | 44 | 76.9 |
| Conservative | 13 | 23.1 |
| Chemotherapy | ||
| Anthracycline+taxane | 42 | 73.1 |
| Anthracycline only | 10 | 17.3 |
| Taxane only | 5 | 9.6 |
| Radiotherapy | ||
| Yes | 44 | 76.9 |
| No | 13 | 23.1 |
Risk factors in group with and without cardiac complications_
| Risk factor | Group with no cardiac complications % Number | Group with cardiac complications % Number | P value | ||
|---|---|---|---|---|---|
| Age | |||||
| >40 | 32.4 | 12 | 70 | 14 | 0.042 |
| <40 | 67.6 | 25 | 30 | 6 | |
| BMI <25 | 43.6 | 16 | 25 | 5 | 0.322 |
| >25 | 56.4 | 21 | 75 | 15 | |
| Hypertension | 0.323 | ||||
| Yes | 24.3 | 9 | 45 | 9 | |
| No | 75.7 | 28 | 55 | 11 | |
| Diabetes | 0.127 | ||||
| Yes | 13.5 | 5 | 45 | 9 | |
| No | 86.5 | 32 | 55 | 11 | |
| Chemotherapy | |||||
| With anthracycline | 91.8 | 33 | 95 | 19 | 1.000 |
| Without anthracycline | 8.2 | 4 | 5 | 1 | |
| Concomitant radiotherapy | |||||
| Yes | 54 | 20 | 75 | 15 | 0.323 |
| No | 46 | 13 | 25 | 5 | |
Characteristics of the LVEF decrease in patients with cardiotoxicity (n = 20)_
| Cardiotoxicity criteria | No. patients | Percentage of patients with cardiotoxicity (%) | Percentage of patient total (%) |
|---|---|---|---|
| LVEF decrease <50% | 8 | 40 | 14 |
| LVEF decrease >10 points below baseline | 17 | 85 | 30 |
| LVEF decrease > 15 points below baseline | 3 | 15 | 5% |